Landscape → Immunology

IBD Clinical Trial Landscape

Data updated: May 20, 2026

102 clinical trials tracked since 2008

IBD is being studied across 102 clinical trials registered since 2008, with 22 programs currently active. The competitive pipeline includes 4 active Phase 3 trials, 12 active Phase 2 trials, and 7 active Phase 1 trials. Top industry sponsors include Disc Medicine, Inc, iCell Gene Therapeutics, Parvus Therapeutics, Inc..

22 active

102 total (since 2008)

Phase 1 Active

35 total

Phase 2 Active

29 total

Phase 3 Active

25 total

Phase 4 Active

20 total

Top Industry Sponsors

Sorted by active Active Done Failed

Disc Medicine, Inc 1 0 0

iCell Gene Therapeutics 1 0 0

Parvus Therapeutics, Inc. 1 0 0

Mirador Therapeutics, Inc. 1 0 0

Wuhan Humanwell Innovative Drug Research and Development Center Limited Company 1 0 0

+ 6 more sponsors — see full table below

Featured Phase 3 Trials

NCT07047339 RECRUITING

Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis

Changhai Hospital n=120

NCT06604273 RECRUITING

Unravelling Intestinal Fibrosis in Ulcerative Colitis

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=10

NCT01022749 COMPLETED

Efficacy Safety Study of Flu Vaccine in Immunodepression Patients

Assistance Publique - Hôpitaux de Paris n=228

NCT01369355 COMPLETED

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Janssen Research & Development, LLC n=1,282

NCT04060303 COMPLETED

ENhanced Recovery in CHildren Undergoing Surgery

Northwestern University n=599

+ 20 more Phase 3 trials — see full database below

IBD — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Disc Medicine, Inc

iCell Gene Therapeutics

Parvus Therapeutics, Inc.

Mirador Therapeutics, Inc.

Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

Resilience

Lmito Therapeutics Inc.

Pharmacosmos A/S

AstraZeneca

Johnson & Johnson

Active Trials by Phase

Phase 1

Phase 2

Phase 3

Phase 4

Enrollment Size Distribution

1-50

51-200

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Disc Medicine, Inc 1 0 0

iCell Gene Therapeutics 1 0 0

Parvus Therapeutics, Inc. 1 0 0

Mirador Therapeutics, Inc. 1 0 0

Wuhan Humanwell Innovative Drug Research and Development Center Limited Company 1 0 0

Resilience 1 0 0

Lmito Therapeutics Inc. 1 0 0

Pharmacosmos A/S 0 5 0

AstraZeneca 0 0 3

Johnson & Johnson 0 3 0

Shield Therapeutics 0 3 0

NCT07582458 NOT YET RECRUITING

Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease: a Multicentre,Randomised, Double-blind, Placebo-controlled, Clinical Trial (MODIFI-IBD Trial)

Radboud University Medical Center n=60

NCT07047339 RECRUITING

Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis

Changhai Hospital n=120

NCT07043036 NOT YET RECRUITING

Randomized Controlled Trial Comparing Remote Patient Monitoring vs Standard Care in IBD Patients Initiating or Changing Advanced Therapy

Resilience n=116

NCT06604273 RECRUITING

Unravelling Intestinal Fibrosis in Ulcerative Colitis

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=10

NCT03961815 TERMINATED

Open-label Extension Study of Brazikumab in Crohn's Disease

AstraZeneca n=18

NCT01022749 COMPLETED

Efficacy Safety Study of Flu Vaccine in Immunodepression Patients

Assistance Publique - Hôpitaux de Paris n=228

NCT01369355 COMPLETED

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Janssen Research & Development, LLC n=1,282

NCT04060303 COMPLETED

ENhanced Recovery in CHildren Undergoing Surgery

Northwestern University n=599

NCT03759288 TERMINATED

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

AstraZeneca n=89

NCT02680756 COMPLETED

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

Shield Therapeutics n=250

NCT01340872 COMPLETED

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)

Shield Therapeutics n=128

NCT01352221 COMPLETED

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)

Shield Therapeutics n=128

NCT01496053 COMPLETED

Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)

Oslo University Hospital n=100

NCT00620126 COMPLETED

The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis

University of Maryland, Baltimore n=47

NCT01692743 COMPLETED

Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)

University of Maryland, Baltimore n=348

NCT03035058 WITHDRAWN

Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease

Takeda

NCT01369342 COMPLETED

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Janssen Research & Development, LLC n=640

NCT01369329 COMPLETED

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Janssen Research & Development, LLC n=769

NCT02771457 WITHDRAWN

Managing Infliximab Reinduction After Temporary Discontinuation of Drug

NYU Langone Health

NCT01428843 TERMINATED

Comparison of Ferrisat vs Placebo in Anemia Associated to Inflammatory Bowel Disease During Anti-TNF Therapy

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives n=60

NCT01599702 COMPLETED

Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease

Pharmacosmos A/S n=21

NCT01410435 COMPLETED

Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease

Pharmacosmos A/S n=39

NCT00810030 COMPLETED

FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR

Vifor Pharma n=484

NCT00810004 COMPLETED

Maintenance Treatment of Iron Deficiency in IBD Patients

Vifor Pharma n=245

NCT01017614 COMPLETED

Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia

Pharmacosmos A/S n=350

NCT07368972 RECRUITING

Study of DISC-0974-201 in Participants With IBD and Anemia

Disc Medicine, Inc

NCT07544160 NOT YET RECRUITING

BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)

iCell Gene Therapeutics

NCT07477782 NOT YET RECRUITING

Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation

Assistance Publique - Hôpitaux de Paris

NCT07300553 RECRUITING

Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

Assistance Publique - Hôpitaux de Paris

NCT07113522 RECRUITING

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

Mirador Therapeutics, Inc.

NCT06599658 RECRUITING

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT03938701 RECRUITING

Fluorescence Imaging of IBD and RA Using Adalimumab-800CW

University Medical Center Groningen

NCT05876182 RECRUITING

Vancomycin in Primary Sclerosing Cholangitis in Italy

University of Milano Bicocca

NCT06604260 RECRUITING

FAPi-PET Imaging of in Vivo Fibrosis in Inflammatory Bowel Disease Patients

Dalia Lartey

NCT03983837 COMPLETED

Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04456517 TERMINATED

Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy

Vanderbilt University Medical Center

NCT03201445 TERMINATED

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

Galapagos NV

NCT03616821 TERMINATED

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

AstraZeneca

NCT01009281 TERMINATED

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

Novartis Pharmaceuticals

NCT00805285 TERMINATED

The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis

University of Maryland, Baltimore

NCT02048137 COMPLETED

Transcranial Direct Current Stimulation to Reduce Chronic Pain in Patients With Chronic Inflammatory Bowel Diseases

Charite University, Berlin, Germany

NCT02433470 COMPLETED

Association of Functional Changes in the Brain and the Perception of Pain in Patients With Chronic Inflammatory Bowel Diseases (IBD)

Charite University, Berlin, Germany

NCT01296841 COMPLETED

Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care

VA Palo Alto Health Care System

NCT01896635 COMPLETED

Faecal Microbiota Transplantation in Ulcerative Colitis

The University of New South Wales

NCT01809275 COMPLETED

Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

Qu Biologics Inc.

NCT01810185 WITHDRAWN

Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease

Santa Barbara Cottage Hospital

NCT01438372 WITHDRAWN

IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD

Wayne State University

NCT01106742 COMPLETED

Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)

Ullevaal University Hospital

NCT00820365 COMPLETED

SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease

4SC AG

NCT03816345 RECRUITING

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

NCT02636517 ENROLLING BY INVITATION

Fecal Microbiome Transplant

Judith Kelsen

NCT07423000 RECRUITING

A Phase 1 Study of PVT401 in Healthy Subjects

Parvus Therapeutics, Inc.

NCT07373457 RECRUITING

A Phase I Study of HW201877 in Healthy Subjects

Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

NCT07177157 NOT YET RECRUITING

The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients

Terry Ponich

NCT05659953 NOT YET RECRUITING

LMT503 First-in-human SAD, MAD, and FE Study

Lmito Therapeutics Inc.

NCT07466940 COMPLETED

A Clinical Study to Evaluate SM17 in Healthy Participants

SinoMab BioScience Ltd

NCT05078879 COMPLETED

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06055023 COMPLETED

Phase I Clinical Study of ZL-82 Tablets

Chengdu Zenitar Biomedical Technology Co., Ltd

NCT05107492 COMPLETED

Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants

Pfizer

NCT01560819 COMPLETED

Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases

Corewell Health West

NCT05638347 COMPLETED

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Atridia Pty Ltd.

NCT02108821 COMPLETED

Fecal Microbiota Transplantation in Pediatric Patients

Children's Mercy Hospital Kansas City

NCT03555617 COMPLETED

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

Theravance Biopharma

NCT03750565 COMPLETED

Multiple Dose Ethnobridging PK Study in Healthy Subjects

Theravance Biopharma

NCT03414788 WITHDRAWN

Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease

Pfizer

NCT02464020 COMPLETED

A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis

University of Minnesota

NCT01851343 TERMINATED

Bone Marrow Stromal Cells for Inflammatory Bowel Diseases

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02487238 COMPLETED

Pediatric FEcal Microbiota Transplant for Ulcerative Colitis

McMaster Children's Hospital

NCT03473626 COMPLETED

Phase 1 Food Effect Study for Alicaforsen Tablets

Atlantic Pharmaceuticals Ltd

NCT01757964 COMPLETED

Bacteriotherapy in Pediatric Inflammatory Bowel Disease

David Suskind

NCT02156557 COMPLETED

Study of KCC Peptide Application in the Colon

Danielle Kim Turgeon

NCT02914262 COMPLETED

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

Aerpio Therapeutics

NCT02391012 TERMINATED

Fecal Transplantation for Inflammatory Bowel Disease

Meir Medical Center

NCT01971814 COMPLETED

Early Serum Infliximab Levels in Severe Ulcerative Colitis.

University of California, San Francisco

NCT01666327 COMPLETED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease

Tanabe Pharma Corporation

NCT01981616 COMPLETED

Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab

Millennium Pharmaceuticals, Inc.

NCT01221818 COMPLETED

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

Eisai Inc.

NCT01213680 COMPLETED

Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease

Pharmacosmos A/S

NCT00742781 COMPLETED

Vitamin D Supplementation in Crohn's Patients

Penn State University

NCT00849368 COMPLETED

Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients

University of Zurich

NCT00868660 COMPLETED

Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

Zealand Pharma

NCT00889161 COMPLETED

Curcumin in Pediatric Inflammatory Bowel Disease

Seattle Children's Hospital

NCT07414199 NOT YET RECRUITING

The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department

Children's Hospital of Orange County

NCT06794944 NOT YET RECRUITING

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

Brigham and Women's Hospital

NCT07161297 NOT YET RECRUITING

Remimazolam for Colonoscopy in IBD Patients

Humanitas Clinical and Research Center

NCT06346288 COMPLETED

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

AbbVie

NCT02437591 COMPLETED

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

Astellas Pharma Europe Ltd.

NCT06224270 WITHDRAWN

Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications

University of Wisconsin, Madison

NCT02994836 COMPLETED

GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

NCT02392286 TERMINATED

Corticosteroid Dosage for Crohn's Disease Flare

Yale University

NCT03466983 COMPLETED

A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Pharmacosmos A/S

NCT00746395 COMPLETED

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

University of South Alabama

NCT02086968 COMPLETED

Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass

American Regent, Inc.

NCT02461758 COMPLETED

Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients

University of Wisconsin, Madison

NCT02453776 COMPLETED

Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT02162862 COMPLETED

Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

Eva Szigethy

NCT01981889 COMPLETED

Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease

University of British Columbia

NCT01934088 COMPLETED

Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy

Copenhagen University Hospital at Herlev

NCT01067547 COMPLETED

A Trial of Iron Replacement in Patients With Iron Deficiency.

Richard Fedorak

NCT02248337 COMPLETED

Low Volume Colon Preparation for IBD

Luigi Sacco University Hospital

NCT01341808 COMPLETED

Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients

Asan Medical Center

NCT01034358 COMPLETED

Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease

Mayo Clinic

Full IBD Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only